Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT06974110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT06974110
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- MOMA Therapeutics
- Industry
- Enrollment
- 132 participants
Conditions and interventions
Conditions
Interventions
- Immunotherapy Drug
- Irinotecan Drug
- MOMA-341 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 15, 2025
- Primary completion
- Oct 31, 2027
- Completion
- Apr 30, 2028
- Last update posted
- Apr 14, 2026
2025 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site #101 | San Diego | California | 92037 | Recruiting |
| Investigative Site #128 | Tampa | Florida | 33612 | Recruiting |
| Investigative Site #120 | Detroit | Michigan | 48201 | Recruiting |
| Investigative Site #110 | St Louis | Missouri | 63108 | Recruiting |
| Investigative Site #131 | Raleigh | North Carolina | 27710 | Recruiting |
| Investigative Site #121 | Portland | Oregon | 97239 | Recruiting |
| Investigative Site #127 | Dallas | Texas | 75230 | Recruiting |
| Investigative Site #129 | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06974110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06974110 live on ClinicalTrials.gov.